Vaccine acquisitions could pave the way for Bavarian Nordic's 2025 ambitions

The biotech company is training its sights on becoming one of the world’s biggest vaccine companies in 2025, when it expects a billion-dollar revenue. To get to this point, Bavarian Nordic has formulated a two-pronged approach.

Photo: Bavarian Nordic / PR

A lot is going on at Bavarian Nordic: the transfer of Glaxosmithkline’s vaccines Rabipur and Encepur, three ongoing clinical cancer studies, the development of RSV and Covid-19 vaccines, an expansion of production facilities in Denmark and a liquid-frozen formulation of the company’s smallpox vaccine.

Ongoing clinical trials and weak sales of the acquired multimillion-dollar travel vaccines Rabipur and Encepur have made for an expensive year, resulting in Bavarian Nordic booking a net deficit of DKK 464.8m (USD 68m) for 2021.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs